Table I.
Association of MARCH1 expression with clinicopathological characteristics in 45 patients with EOC.
| Characteristics | No. of pts. (n=45) |
MARCH1 expression
|
P-value | |
|---|---|---|---|---|
| Low no. (%) |
High no. (%) |
|||
| Age (years) | 0.913 | |||
| <51 | 28 | 12 (42.86) | 16 (57.14) | |
| ≥51 | 17 | 7 (41.18) | 10 (58.82) | |
| FIGO stage | 0.625 | |||
| I–II | 36 | 16 (44.44) | 20 (55.56) | |
| III–IV | 9 | 3 (33.33) | 6 (66.67) | |
| Grade | 0.202 | |||
| 1–2 | 24 | 8 (33.33) | 16 (66.67) | |
| 3 | 21 | 11 (52.38) | 10 (47.62) | |
| Tumor type | 0.971 | |||
| Serous | 38 | 16 (42.11) | 22 (57.89) | |
| Non-serousa | 7 | 3 (42.86) | 4 (57.14) | |
MARCH1, membrane-associated RING-CH; EOC, epithelial ovarian cancer; pts., patients; FIGO, International Federation of Gynecology and Obstetrics.
a
Non-serous EOC included mucinous, clear and endometrioid cancer.